Development and validation of a cost-utility model for Type1 diabetes mellitus

被引:8
|
作者
Wolowacz, S. [1 ]
Pearson, I. [1 ]
Shannon, P. [2 ]
Chubb, B. [3 ]
Gundgaard, J. [4 ]
Davies, M. [5 ]
Briggs, A. [6 ]
机构
[1] RTI Hlth Solut, Hlth Econ, Manchester, Lancs, England
[2] RTI Hlth Solut, Patient Reported Outcomes, Manchester, Lancs, England
[3] Novo Nordisk Ltd, European Hlth Econ & Outcomes Res, Gatwick, W Sussex, England
[4] Novo Nordisk AS, Hlth Econ & HTA, Bagsvaerd, Denmark
[5] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England
[6] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
关键词
RISK-FACTORS; COMPLICATIONS; DISEASE; NEUROPATHY; EURODIAB; COHORT; ONSET;
D O I
10.1111/dme.12663
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsTo develop a health economic model to evaluate the cost-effectiveness of new interventions for Type1 diabetes mellitus by their effects on long-term complications (measured through mean HbA(1c)) while capturing the impact of treatment on hypoglycaemic events. MethodsThrough a systematic review, we identified complications associated with Type1 diabetes mellitus and data describing the long-term incidence of these complications. An individual patient simulation model was developed and included the following complications: cardiovascular disease, peripheral neuropathy, microalbuminuria, end-stage renal disease, proliferative retinopathy, ketoacidosis, cataract, hypoglycemia and adverse birth outcomes. Risk equations were developed from published cumulative incidence data and hazard ratios for the effect of HbA(1c), age and duration of diabetes. We validated the model by comparing model predictions with observed outcomes from studies used to build the model (internal validation) and from other published data (external validation). We performed illustrative analyses for typical patient cohorts and a hypothetical intervention. ResultsModel predictions were within 2% of expected values in the internal validation and within 8% of observed values in the external validation (percentages represent absolute differences in the cumulative incidence). ConclusionsThe model utilized high-quality, recent data specific to people with Type1 diabetes mellitus. In the model validation, results deviated less than 8% from expected values. What's new? A simple cost-utility model was developed to evaluate new interventions for Type1 diabetes mellitus by assessing the association between the interventions' effects on mean HbA(1c) and long-term complications and the risk of hypoglycaemic events. High-quality, recently reported data specific to people with Type1 diabetes mellitus were identified by a systematic review. Model validation included review by clinical and economic experts, verification of input data and formulae, and comparison of model predictions with observations from studies used to build the model and other published data.
引用
收藏
页码:1023 / 1035
页数:13
相关论文
共 50 条
  • [31] ASSESSING THE COST-UTILITY OF ETELCALCETIDE: A MARKOV MODEL
    Stollenwerk, B.
    Iannazzo, S.
    Akehurst, R.
    Adena, M.
    Briggs, A.
    Dehmel, B.
    Parfrey, P.
    Belozeroff, V
    VALUE IN HEALTH, 2016, 19 (07) : A519 - A519
  • [32] A COST-UTILITY MODEL FOR RENAL TRANSPLANTS IN COLOMBIA
    Rosselli, D.
    VALUE IN HEALTH, 2009, 12 (07) : A484 - A484
  • [33] Development and Validation of a Nocturnal Hypoglycaemia Risk Model for Patients With Type 2 Diabetes Mellitus
    Gong, Chen
    Cai, Tingting
    Wang, Ying
    Xiong, Xuelian
    Zhou, Yunfeng
    Zhou, Tingting
    Sun, Qi
    Huang, Huiqun
    NURSING OPEN, 2024, 11 (10):
  • [34] Urine Heat Shock Protein 70 levels in chidren with type1 diabetes mellitus
    Emre, Sevinc
    Yilmaz, Alev
    YurukYildirim, Zeynep
    Seker, Basak
    Gedikbasi, Asuman
    Pehlivanoglu, Cemile
    Sucu, Aysegul
    Bundak, Ruveyde
    PEDIATRIC NEPHROLOGY, 2013, 28 (08) : 1420 - 1420
  • [35] Compromised quality of life in patients with both Type1 diabetes mellitus and coeliac disease
    Bakker, S. F.
    Pouwer, F.
    Tushuizen, M. E.
    Hoogma, R. P.
    Mulder, C. J.
    Simsek, S.
    DIABETIC MEDICINE, 2013, 30 (07) : 835 - 839
  • [36] COST-UTILITY ANALYSIS OF INSULIN DEGLUDEC VS. INSULIN GLARGINE U100 TREATMENT IN PATIENTS WITH DIABETES MELLITUS TYPE 1 AND 2 IN SERBIA
    Culic, M.
    Russel-Szymczyk, M.
    Chubb, B.
    Tikkanen, C.
    VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [37] The Determination of Diabetes Utilities, Costs, and Effects Model: A Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes: Comparative Validation
    Szafranski, Kirk
    De Pouvourville, Gerard
    Greenberg, Dan
    Harris, Stewart
    Jendle, Johan
    Shaw, Jonathan E.
    Castro, JeanPierre Coaquira
    Poon, Yeesha
    Levrat-Guillen, Fleur
    VALUE IN HEALTH, 2024, 27 (04) : 500 - 507
  • [38] Health-Related Quality of Life in Children and Adolescents with Type1 Diabetes Mellitus
    Alkhouli, Laila
    Al Remeithi, Sareea
    Al Jeneibi, Sara
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 : 180 - 181
  • [39] Evaluation of the use of different insulin regimens in the treatment of type1 and type 2 diabetes mellitus.
    Al Hakim, Maha Mahmoud
    Abasaeed, Abobakr
    Jones, Jones
    PHARMACOTHERAPY, 2012, 32 (10): : E202 - E202
  • [40] Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland
    Braendle, M.
    Azoulay, M.
    Greiner, R.-A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (04) : 203 - 220